BioXcel Therapeutics (BTAI) investor relations material

Unmet need in acute agitation for Alzheimer's dementia

• Acute agitation episodes in Alzheimer's dementia are common, unpredictable, and lack FDA-approved treatments, creating a significant gap for patients and caregivers.

• Current management relies on off-label sedatives and antipsychotics, which carry safety risks and can impair quality of life.

• Acute agitation can occur in both patients with and without chronic agitation, often leading to emergency room visits and increased healthcare utilization.

BXCL501 clinical profile and potential impact

• BXCL501, a dexmedetomidine oral film, met its primary efficacy endpoint in a phase III trial for acute agitation in Alzheimer's dementia and was well-tolerated.

• The drug offers rapid onset of action, with effects seen within 30–60 minutes, and avoids heavy sedation or increased fall risk.

• Its sublingual film format is easy to administer, even in moderate to advanced dementia, and is preferable to injections or pills.

• BXCL501 does not carry the antipsychotic box warning for increased mortality, making it more appealing for clinicians.

Market opportunity and care benefits

• The aging population and rising Alzheimer's prevalence create a growing need for acute agitation solutions across home, assisted living, and nursing facilities.

• BXCL501 could reduce emergency visits, delay institutionalization, and ease caregiver burden by enabling better management of episodic agitation.

• The drug's safety profile, ease of use, and lack of significant drug interactions support its use alongside chronic agitation therapies.

• Cost and insurance reimbursement may be initial challenges, but high adherence and ease of training are expected.